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ABSTRACT 
Madkhali, Mariyyah Ahmed O., M.S., Department of Pharmacology and Toxicology, 
Wright State University, 2020. Multiple genotoxic agents activate ATR kinase signaling in 
quiescent human cells. 
 
  The ATR protein kinase is activated in response to DNA damage and other forms 
of genotoxic stress caused by both environmental carcinogens and anti-cancer drugs. 
However, much of our understanding of ATR kinase function is limited to proliferating 
cells in which DNA replication stress is the primary signal for ATR activation and where 
the major regulatory targets of ATR signaling are proteins involved in DNA synthesis and 
cell cycle progression. Here we have used HaCaT keratinocytes maintained in a non-
replicating, quiescent state in vitro to examine how cell killing by different genotoxic 
agents is impacted by cell growth status and by treatment with small molecule ATR kinase 
inhibitors. The genotoxins we examined included drugs from several classes of anti-cancer 
agents, including topoisomerase inhibitors (camptothecin, etoposide), alkylating agents 
(mitomycin C, temozolomide, and cisplatin), and compounds that interfere with RNA 
polymerase movement ((5-6-dichlorobenzimidazole 1-beta-D-ribofuranoside), 
actinomycin D). As expected, we find that quiescent cells are more resistant to the acute, 
lethal effects of these genotoxins than replicating cells. However, though we find that 
nearly all of these compounds led to the activation of ATR kinase signaling in the quiescent 
state, little-to-no effect of ATR kinase inhibitors was observed on quiescent cell viability. 
These results indicate that ATR can be activated in the absence of canonical replication 
stress and that its function does not significantly impact acute cell survival. To examine 
  iv 
potential alternative functions for ATR signaling in quiescent cells, we then examined how 
ATR kinase inhibition impacted the activation of the translesion synthesis (TLS) pathway 
of DNA synthesis, which involves the use of specialized, potentially mutagenic DNA 
polymerases to fill in DNA repair gaps and complete DNA repair. Interestingly, we found 
that ATR kinase inhibition potentiated the activation of this pathway in response to 
mitomycin C and cisplatin but not following treatment with other genotoxins. Both 
mitomycin C and cisplatin induce the formation of DNA adducts that are repaired by the 
nucleotide excision repair system, and thus these results suggest that the ATR kinase may 
be required to limit the dependence on mutagenic TLS DNA polymerases in quiescent 
cells. Because ATR kinase inhibitors are currently being tested in clinical trials for use in 
anti-cancer therapies, this work provides valuable information on the positive and negative 
consequences of ATR kinase inhibition in quiescent or slowly growing cancer cells. 
 Keywords: DNA damage response, ATR kinase inhibition, DNA damaging agents, 
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INTRODUCTION 
1- DNA damage and DNA repair mechanisms. 
a. DNA damage: 
 
 Human cells are continually exposed to many compounds that cause 
damage to deoxyribonucleic acid (DNA) (1). DNA damage changes the structure 
of DNA either physically or chemically to disrupt the function and the genomic 
integrity of DNA (2). Thus, the damage of DNA can be exogenous ways or from 
external environments, such as ultraviolet light, ionizing radiation, and 
chemotherapies. Besides, the damage of DNA can be endogenous ways or from 
internal metabolic ways, such as reactive oxygen species or replication stress (3,4). 
  If the DNA of cells has been damaged, they leave lesions on the site of the 
damaged area. The different types of genotoxic agents cause a variety of types of 
DNA damages (3). These lesions have many types such as lesions to nucleotides, 
single-strand break, double-strand break, inter-and intra- strand DNA crosslinks, or 
DNA adduct (2). Then, recognition of DNA damage to begin DNA damage 
responses by specific DNA repair proteins to initiate repair of DNA lesions, which 
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b. DNA repair mechanisms: 
Every lesion has a specific type of DNA repair mechanisms. These include 
mismatch repair, base excision repair, nucleotide excision repair, single and double-strand 
break repair mechanisms (figure 1) (3). DNA repair mechanisms are essential because 
deficiency in repair leads to increased human pathogenesis, such as cancers (table 1) (4,5).  
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Mismatch repair is fixing the damage of deletion or insertion of nitrogenous bases 
through replication on the newly synthesized DNA by slipping polymerases (1-3). These 
DNA polymerases interact with proliferating cell nuclear antigen (PCNA), which is a 
loading clamp for DNA polymerases to fill gaps. Then, DNA ligase seals nick of the DNA 
(6). If there is defect of human genes that effect to mismatch repair, these lead to increase 
mutation rate and linked to inherited colon cancer in humans (3,6,7,30).  
Base excision repair (BER) is the most common pathway that cuts out a single 
nucleotide base by removing the damaged base from the DNA backbone. This occurs when 
single bases are damaged by alkylated or oxidizing agents that modified the nitrogenous 
base (3,6). It is started by a DNA glycosylase enzyme that detects and removes the 
damaged base. Then, an apurinic-apyrimidinic (AP) endonuclease and a phosphodiesterase 
recognize and remove the sugar phosphate that have a missing base by leaving a single 
base gap (6). After that, DNA polymerase and DNA ligase add the correct nucleotide as a 
cytosine and seals nick in the DNA helix (1-3). Examples of DNA damaging agents that 
cause this type of damage are X-rays, hydrogen peroxide, and alkylating agents, such as 
cisplatin, mitomycin C and temozolomide. The defective of BER leads to an increase in 
mutation rates, ataxia and neurodegeneration, which is genetic neurodegenerative disorder 
that effect the coordination of voluntary movement and immune system (7,30). 
Nucleotide excision repair (NER) is the second major DNA repair which is 
correcting the damage of bulky nucleotides caused by UV radiation and carcinogen 
benzopyrene which is found in tobacco smoke or coal tar (1-3,7). Aziz Sancar characterized 
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the mechanism of NER and won a Nobel prize in chemistry in 2015 (3). This led bulky 
lesions to pyrimidine dimers as cytosine to cytosine, thymine to thymine, or thymine to 
cytosine causes thymine bases to react with each other to cause dual incision (6,31,32). 
Then, excision nuclease is a complex enzyme which detects and scans the damaged 
nucleotides in the double helix instead of a single nucleotide base as in base excision repair 
(3). After that, it comes DNA helicase that cuts around 25-30 nucleotides in humans and 
leave gap (31,32). Then, DNA polymerase and DNA ligase add new and correct 
nucleotides and seals gap in the DNA helix (7). The example of human disease that linked 
with defect in this repair is xeroderma pigmentosum (XP) which is affecting humans who 
have high sensitivity to ultraviolet radiation that lead to increase mutation rate and skin 
cancer. There are two pathways of NER are transcription-coupled NER repair and global 
genomic repair to recognize DNA damage (30-32). 
 Transcription-coupled NER repair (TC-NER) targets DNA damage in transcribed 
DNA (3,6). This pathway involves RNA polymerase which is an enzyme that transcribes 
DNA to RNA that repair the damaged nucleotides and using coupling proteins at stalls of 
RNA polymerase (31, 32). An example of a defect of this repair is Cockayne syndrome 
which has symptoms of high sensitivity of sunlight, growth abnormality (growth, skeletal 
and progressive neural retardation) but it is not susceptible to cause skin cancer (3,6).  
However, global genomic repair (GG-NER) targeted the both transcribed and not-
transcribed DNA (29-30). It occurs when xeroderma pigmentosum C (XPC) recruited the 
downstream proteins as xeroderma pigmentosum A (XPA), xeroderma pigmentosum 
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D(XPD), and Human transcription factor IIH subunit 5. Then, XPA recruits replication 
protein A (RPA) to recognize DNA damage and fill gaps by DNA polymerases. The last, 
DNA ligase comes to seal the nick of DNA (6,31,32). An example of a defect of this repair 
is Trichothiodystrophy is neurodegeneration disorder which characterized with brittle hair, 
extremely UV light sensitivity, growth and mental retardation (6). 
Double strand DNA break is the most dangerous type of DNA damage because it 
involves break of the both strands of the double helix and can cause rearrangement of 
chromosomes leading to increased mutations rates and cancer development (3,6). The 
examples of DNA damaging agents that cause this damage are X-rays, ionizing radiation 
and chemotherapies, such as cisplatin and mitomycin C (3,6). Ataxia telangiectasia (AT) 
is a rare inherited disease that characterized of acute sensitivity to radiation and X-rays, 
genomic instability, immunodeficiency, and susceptible to cancers. AT is a defect in double 
strand repair and loss in ATM protein kinase which activated by double strand break (3,29-
32). Correcting the double strands breaks occurs by either homologous recombination (HR) 
or non-homologous end-joining (NHEJ) pathways (3).  
  HR uses a normal sister chromatid as a template to repair dsDNA breaks and to 
allow an accurate error-free repair of the DNA, which occur in S and G2 phases of the cell 
cycle (1-3,6). Thus, it is essential for proliferating cells or replication cells because it cause 
stalled in DNA replication forks that arising from UV light and alkylating agents (1,29). In 
addition, HR is playing an important role in sexually reproducing organisms, especially in 
sperms and eggs production during meiosis in gametes step (30). Thus, defective HR repair 
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is linked to ovarian, breast, and prostate cancers (1).  It is linked to Seckel’s syndrome 
which is rare genetic disorder of dwarfism that characterized with microcephaly, growth, 
mental retardation (6). In addition, it correlates to Fanconi anemia (FA) which is an 
inherited genetic disease that is characterized with defect in birth, bone marrow failure 
which leads to anemia (1,3,6). HR occurs when the daughter duplex DNA helix close to 
the broken double DNA stands in replication of DNA. After nuclease enzyme cuts out the 
ends of broken double strands of DNA, the strand exchange by complementary base pairing 
through DNA polymerase from damaged strands that is using the correct repairing with the 
undamaged daughter as template. The last step is DNA ligase to seal the gaps between the 
two strands of DNA (7,30). 
  In contrast, NHEJ does not required another sister chromatid to fix that repair by 
direct ligation, and it occurs in all phases of the cell cycle (3,6). It is a prone-error process, 
which can induce mutation in the DNA. The initiation and recognition of NHEJ repair 
mechanism by Ku heterodimer protein which is a protein to hold the double strands break 
or the broken ends of chromosomes. Then, the additional proteins come to hold the broken 
ends and processing of DNA ends which the KU heterodimer recruit DNA-dependent 
protein kinase, catalytic subunit (DNA-PKcs) (1-3,6). Eventually DNA ligation to seal the 
DNA nick with deleted of nucleotides which lead to mutation and changes in DNA 
sequence. There is relation between deficiency of NHEJ repair and deficiency of adaptive 
immune system. That is because in NHEJ repair mechanism involves the Ku protein which 
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is essential in recombination of V, D, and J joining segments antibodies and T cells 
receptors (1,30). 
 Inter-strand cross link repair is cross link between two strands to form break in 
double strand of DNA which lead chromosomal rearrangement (3,6).  It is considered toxic 
because it blocks replication and transcription of DNA that leads to arrest of the cell cycle 
and cell death (6). In non-replicating cells, which are in G0-G1 phase, DNA adducts may 
be repair occurs via NER (6). However, in replicating cells, which are in S phase, crosslink 
repair occurs by two repair mechanisms. First, when crosslink occurs in replication forks 
stall to recruit endonuclease to cut it to form double stand DNA break to repair by HR and 
translesion synthesis polymerase (TLS). Second, After TLS polymerase filled the gaps 
followed NER to end repair. In replicating cells is more toxic than in non-replicating cells 
because has robust effect to replication (6,33,37)  
 However, DNA repair mechanisms are the one of the responses to sense and repair 
DNA damage, and to maintain genomic stability. These responses are known as DNA 
damage responses that has four ways to detect and fix DNA lesions. DNA repair 
mechanisms are important because some human’s disease that linked to defect in DNA 
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Table 1: Summary of DNA damage, DNA repair and examples of human disease with 
defect in DNA repair. 
Type of DNA damage DNA repair 
mechanisms 
Some disease in defects in 
DNA repair mechanisms 
1- Single strand break-insert or 




2-  Single strand break-
deamination from cytosine to 
uracil base.  
Base excision 
repair(BBR) 
  Ataxia and 
neurodegeneration 















Ataxia telangiectasia (AT), 
Fanconi anemia (FA), 
Seckel’s syndrome, 
ovarian, breast, and prostate 
cancers. 
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5- Translesion DNA synthesis DNA damage 
tolerance 
Xeroderma pigmentosa (XP) 
variant 
    
2- DNA damage response vs. DNA damage tolerance. 
a) DNA damage response (DDR): 
 
 The DNA damage response (DDR) is a network of protein kinase signaling 
pathways that detect and repair DNA lesions (21). DDR recognizes theses different types 
of genotoxic agents by four responses (2,3). These are cell cycle checkpoints activation, 
DNA repair mechanisms, transcriptional response, and cell death or senescence if damage 
cannot repair (4, 16, 24). Thus, DDR has crucial role in maintaining genomic stability and 
cell viability (5, 21).  
After DNA is damaged, DNA damage sensors are activated, and checkpoints 
activated. DNA damage response is a complex signaling pathways that activate 
checkpoints through a family of phosphoinositide 3 kinase-related kinases (PIKKs) (4,5). 
There are three subgroup protein kinases in human cells, which is controlled by the DNA 
damage response (3,6,7,25,26). These are DNA-dependent protein kinase (DNA-PK), 
ataxia telangiectasia mutated (ATM), and ataxia telangiectasia and rad3-related (ATR).  
ATM and DNA-PK have known to be recruited when DNA damage in double strand DNA 
break while ATR protein kinase have known be recruited after DNA damage in single 
strand DNA break. (16-19) Thus, these proteins sense DNA damage to repair DNA, cell 
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cycle regulation, DNA replication, transcription regulation, RNA processing, and inducing 
cell death (figure 2) (7,8,9). 
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  ATM and ATR have common phosphorylation substrate proteins which are 
involved in regulation and activation which consider overlap between these protein kinases 
through checkpoint kinase 1(CHK1) and checkpoint kinase 2(CHK2) (6,16-17). The 
components of DNA damage checkpoints are sensors, signal transducers, and effectors 
(figure 3) (2). Sensor proteins are the first to recognize the damaged DNA to repair and 
stop the progression of the cell cycle. These are ATR, ATM, the RFC/PCNA (clamps 
loader/polymerase clamp)-related Rad 17-RFC/9-1-1 complex, and RPA. Then comes 
mediators along with sensors to help signal transducers and effectors to affect cellular 












Figure 3: DNA damage checkpoints in human cells. 
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However, ATM protein kinase is not essential protein because loss of ATM gene 
cause (A-T) ataxia telangiectasia whereas ATR is essential protein because loss of ATR 
gene cause death of embryonic in early stage of life (6). Thus, ATR-checkpoint kinase 
signaling is more common signaling pathway because it involves single strand breaks, 
which is the most common DNA damage that occur around 10,000 lesions per cell per day 
(6). and resected single strand break which involve checkpoints kinases (16-19). 
b) DNA damage tolerance (DDT): 
 
In DNA damage tolerance (DDT), some DNA lesions escape from repair 
mechanisms and have longer time to add mismatch nucleotides opposite to damaged DNA 
template to help bypass DNA lesions via specific polymerases. Lesion bypass by 
(Ubiquitination PCNA) has two ways: 1- PCNA poly-ubiquitination; Error-free template 
switching (TS). 2- PCNA mono ubiquitination; Error-prone translesion synthesis (TLS), 
which leads to increase mutation (figure 4) (41-43,48).   
Translesion synthesis (TLS) is one of DNA damage tolerance that bypass lesions 
through translesion DNA polymerases in DNA replication and escape from DNA repair 
mechanisms such as base excision repair, nucleotides excision repair or mismatch repair 
(1,30). However, DNA polymerase is correcting the wrong nucleotides by adding the 
correct nucleotides on the undamaged complementary strand and it is not fixing the 
damaged nucleotides on template strand of DNA. Thus, the TLS pathway can increase 
mutagenesis, genomic instability and apoptosis because TLS is error prone that recruited 
PCNA-mono-ubiquitination which the ubiquitination of PCNA is an essential role in 
  13 
regulating from template switching (TS) to translesion DNA synthesis (TLS), which is a 
damage avoidance pathway and it is error free (1,27-28,30-32).   
 TLS involves two type of DNA polymerases. These are polymerase switching and 
DNA extension past the lesion. In polymerase switching, which involve the high-fidelity 
DNA polymerase such as Pol delta to come along with PCNA in replication fork and to 
assist leading and lagging DNA strand synthesis (31,32,41-43,48).Then, these polymerases 
are replaced with the low fidelity DNA polymerase such as in Y-family (TLS) polymerase; 
Ubiquitin-binding Zinc finger (POL eta, and POL kapa) and helical ubiquitin-binding 
motifs (Rev1) to fill gaps via putting mismatch nucleotide across from lesions to help 
bypass lesions (31,32,). Hence, translesion synthesis (TLS) DNA polymerases will interact 
with PCNA only if PCNA is mono-ubiquitinated (41-43,48). The example of some 
inherited disease that effect humans who have defect in translation DNA synthesis, 
especially in polymerase eta is Xeroderma pigmentosa variant which effecting humans who 
have high sensitivity to UV light and they are susceptible to have skin cancer (1,30) (table 
1). 
However, TLS is most recognized for its function in S phase in replicating cells as 
described in previous studies (1,30,41-43,48). However, TLS polymerase recruitment to 
sites of DNA damage has recently been shown to occur in non-replicating G0-G1 phase as 
well (27,28,51,52). In non-replicating cells, TLS pathway has been shown that polymerase 
specialized DNA synthesis as pol kapa, which is responsible to fill gaps by NER to prevent 
the single strand DNA break from conversion to double strand DNA break, which is the 
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most dangerous and toxic DNA lesion (51, 54). Thus, the TLS pathway is dependent on 
mono-ub-PCNA and specialized polymerase DNA synthesis as pol eta, which recruited 
















Figure 4: DNA damage response vs. DNA damage tolerance. ATR-Checkpoint 
kinase, which is the key regulator of DNA damage response, and ubiquitination of 
PCNA, which is the key regulator of DNA damage tolerance. They activated after 
replication protein A recruited at replication forks stall in a single strand DNA. 
Ubiquitination of PCNA at lysine residue at lysine 146 has two major lesion bypasses. 
These are Poly-ubiquitination -PCNA, which is error-free template switching (TS) 
bypass and mono-ubiquitination-PCNA, which is error-prone translesion DNA 
synthesis (TLS) leading to increase mutagenic cell survival. 
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3- Ataxia telangiectasia and Rad3-related activation and inhibition in 
replicating cells vs. non-replicating cells. 
a. ATR kinase in replicating cells. 
 
  ATR is ataxia telangiectasia and Rad3-related is activated after cells are exposed 
to genotoxic agents to sense and activate DNA damage response kinase pathway (21). It is 
one of the phosphatidylinositol-3 kinase-related kinase (PIKKs), which is a member of the 
phosphatidylinositol3- kinase family (PI3K) (13,14). These are serine/ threonine kinase, 
which are upregulated in a different type of cancer development and function in the ATR-
CHK1 pathway. (16-19). The activation of ATR plays a crucial role in DNA repair, 
inhibiting replication fork stabilization, decreasing in replication origin firing, and cell 
cycle inhibition by activation of intra-S and G1/M checkpoints (10,11-15). 
There are three-ways to induce ATR-CHK1 pathway activation and downstream 
signaling (21-24). First, induction of ATR by increasing replication stress that causes a 
stalled in replication fork by breaking in a single strand of DNA in S phase in replication 
cells through topoisomerase 1 inhibitor (camptothecin), alkylating agents, or hydroxyurea 
(10-13,21-24). Second, UV and cross-linking agents that causes bulky DNA adducts by 
nucleotide excision repair (NER) at stalled replication forks in single strand DNA break 
through alkylating agents (10-13,21). Moreover, an additional pathway that may activate 
ATR is transcription stress caused by RNA polymerase stalling, which recruited 
transcriptional coupled nucleotide excision repair (TC-NER) through phosphorylation of 
transcription factor p53 at ser-15 site. Examples of transcriptional stressors that 
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phosphorylate p53 is actinomycin D and 5,6-Dichlorobenzimidazole 1-beta-D-
ribofuranoside (DRB) (25,26,34). Third, the activation of ATR-check point by breaking in 
a double strand of DNA through topoisomerase II inhibitors (Etoposide) or ionizing 
radiation which they cause resected in double-strand DNA break to be involved in the 
process of HR (10-13,21-24).  
Therefore, ATR steps happen once it is triggered by single-stranded DNA gaps 
(ssDNA), which are primarily responsible for signaling of DNA damage (21-24). Then, 
Replication protein A (RPA) coats ssDNA, which is localization in the site of DNA 
damage. RPA recruits the ATR-interacting protein complex, which is phosphorylated by 
ATR to recruited DNA topoisomerase II-binding protein 1 (TOPBP1) and claspin/9-1-
1which are protein adaptors to activate ATR via phosphorylate checkpoint (CHK1) (11-
15). Finally, it has essential roles in DNA repair, cell survival, DNA replication, and cell 
cycle progression. Most of the known activation mechanisms and functions of ATR kinase 
involve DNA replication and cell cycle progression through S/M stage in the cell cycle 
(10-15,25-28). 
ATR kinase inhibition prevents ATR-checkpoint kinase signaling pathway, which 
leads to inhibit of DNA repair and cell cycle arrest and induce cell death through using 
small molecule inhibitors, such as VE-821, VE-822, and/or AZD678 to decrease tumors 
activity and DNA damage (11,21). Theses inhibitors are blocking ATR-CHK1 signaling 
pathways which leads to prevent checkpoint activation, DNA repair, DNA replication 
(origin firing), fork stabilizing, and deoxynucleotides pools (dNTPs) (figure 5) (12). 
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However, ATR kinase activation and inhibition have primarily been studied in cells 
that actively synthesizing DNA, such as during the S phase of cell cycle. Thus, ATR kinase 
protein can protect cells from lethal effects in response of replication stress. In contrast, 
ATR kinase inhibition can promote cells to lethal effects when exposed to genotoxins (25-
28). Most of researches have been shown that ATR has only functions and activated only 
in the replication stage (S phase) of cell cycle (figure 6) (25.26,33,34). 
b. ATR kinase in non-replicating cells. 
   The most of ATR kinase activation and inhibition in non-replicating quiescent cells 
are undiscovered yet or not completely understood. Thus, a few articles have been studied 
that ATR can be activated in non-replicating quiescent cells, which in G0-G1phase in the 
cell cycle (figure 6) (25,26,33,34). However, quiescent cells are essential to study because 
of the majority of human cells and cancer stem cells in the G0-G1 cell cycle in the non-
replication stage, which DNA not actively proliferating through cell cycle progression. In 
contrast, a few human cells are in the replicating stage (25,26,33,34). Thus, Dr. Kemp had 
found that ATR kinase inhibition partially protects quiescent HaCaT cells treated with N-
acetoxy-2-acetylaminofluorene (NA-AAF), which generates bulky adducts on guanines in 
DNA. He had shown that ATR kinase inhibition has opposite effects on the viability of 
replicating and non-replicating cells (25,26). 
 A few previous studies have focused on agents that induce DNA lesions repaired 
via NER and have suggested a possible reliance on the TLS pathway that promote 
mutagenesis in quiescent cells (27,28,33,34).  Dr. Kemp’s lab has been found recently that 
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ATR kinase inhibition sensitizes quiescent cells to the lethal effects of cisplatin or UVB, 
but ATR inhibition caused an increase in PCNA mono-Ub, which it is a marker of 
activation of the translesion synthesis (TLS) pathway, which is potentially mutagenic after 


























Figure 6: ATR activation and inhibition in replicating cells vs. non-replicating 
cells. ATR kinase can activate after it exposed to DNA damage either in 
proliferating cells in S phase or in non-replicating quiescent cells. In 
proliferating cells, ATR activated after replication stress to lead to protect cell 
from lethal effects when it exposed to genotoxins but in inhibition of ATR kinase 
can promote cells to apoptosis or cell death when exposed to genotoxic 
compound. However, in quiescent cells, ATR kinase activation and inhibition 
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4- ATR inhibitors. 
ATR inhibitors are inhibiting ATR-checkpoint signaling pathway in response of 
DNA damage with or without DNA damaging agents to decrease cancers development (21-
24). ATR kinase inhibitors are currently ongoing in clinical trials with different types of 
chemotherapies to treat human cancers patients (20,25-28).  
The first ATR inhibitor was 3-amino-6-arylpyrazines, which known as VE-821 that 
developed by Vertex Pharmaceuticals in 2011 and it has antitumor activity (21). It has 
selectivity and potency to inhibit ATR protein kinase and ATR-CHK1 signaling pathway. 
It has synergistic effects and sensitization effect to inhibit ATR which targeted cancer cells 
but not to normal cells. VE-821 had been demonstrated in preclinical studies with radiation 
and chemotherapies such as cisplatin, gemcitabine, topotecan, doxorubicin, and 
camptothecin (table1) (11-23). 
  The second ATR inhibitor was VE-822; M6629 which developed by Vertex 
Pharmaceutical and it was the first ATR inhibitor to undergo clinical trials as VX-970. It 
is an analogue of VE-821 and it has more selectivity and potency of ATR inhibitor. It 
sensitizes and synergizes cancer cells with or without radiation and chemotherapies such 
as cisplatin (for gastric cancer, lung cancer, and head and neck squamous cell carcinoma), 
Camptothecin, topotecan, irinotecan, (for colorectal cancer patients) gemcitabine, 
etoposide (for lung cancer patients) (table1) (11-24). 
The third ATR inhibitor was AZD6738 that was developed by AstraZeneca and it 
is an analogue of AZ20. It has the highest selectivity and potency to inhibit ATR kinase 
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and ATR-CHK1 signaling pathways. It is the first drug which is administered orally. It is 
the second ATR inhibitor which undergoes clinical trials in combination with 
chemotherapies or alone. It is sensitizing and synergizes tumor cells with or without 
radiation and chemotherapies, such as paclitaxel, carboplatin, olaparib, or durvaumab 
(table1) (11-24). 











Description   It is the first selective 
ATR inhibitor and 
potent. It was 
discovered by vertex 
pharmaceutical 
company in 2011. It 
sensitizes cancer cells 
rather  than normal 
 It is an analogue of 
VE-821 and it has 
more selectivity and 
potency of ATR 
inhibitor. It is the first 
ATR inhibitors that 
undergo clinical trials 
with combination 
 It is an analogue of 
AZ20 and it is having 
the highest potency 
and the highest ATR 
inhibitor selectivity. 
It is the first drug 
which is 
administered orally. 
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cells with 
chemotherapies and 
ionization radiation.    
with chemotherapies 
and ionization 
radiation. It is 
sensitizing cancer 
cells rather than 
normal cells with 
chemotherapies and 
ionization radiation.                      
It is the second ATR 
inhibitor which 
undergoes clinical 
trials in combination 
with chemotherapies 
or alone. It is also 
sensitizing cancer 
cells rather than 
normal cells with 
chemotherapies and 
ionization radiation.   
       
Clinical 
trials 
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Target and 
function 
All three ATR inhibitors prevent DNA damage checkpoint signalling 
activity of ATR/Chk1.Thus, ATR inhibitors inhibit DNA damage 





1- Genotoxic compounds. 
Genotoxic agents are classified as four major classes according to the 
cellular level that we have been tested them at the Dr. Kemp’s lab with ATR kinase 
inhibitors. They are alkylating agents, topoisomerase inhibitors, transcription stress 
inducing compounds, and translational inhibitor (figure 7). Thus, from the central 
dogma of cells’ life, there are two main process to replicate and transcribes DNA 
to RNA, and to translate RNA. In the first step is transcription which begun in 
nucleolus in DNA to be replicated and transcribed to messenger RNA (mRNA). 
Then, in the translation processes, mRNA transfer to cytoplasm at a ribosome to 
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Figure 7: Genotoxic agents in the cellular level. Alkylating agents (cisplatin, 
mitomycin c, temozolomide) inhibited replication of DNA at the cellular level as 
well as topoisomerase inhibitors (camptothecin, etoposide). Transcriptional 
stressors (actinomycin D, 5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside) 
prevented transcription of messenger RNA to transfer to cytoplasm whereas 
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As in a diagram of different classes of genotoxic agents which effect in the cellular 
level. Alkylating agents and topoisomerase inhibitors inhibit replication of DNA at the 
cellular level. Then, transcriptional stressors prevent transcription of the mRNA. The last 
class is translational stressor which inhibit mRNA to transfer to protein as shown in (figure 
7) (25,26). 
a. Alkylating agents: 
Alkylating agents have an alkyl group to attach to DNA or RNA and result in the 
inhibition of DNA, RNA, or protein synthesis. Thus, inhibiting replication on S phase and 
replication in G1 phase. The example of alkylating agents as mitomycin C, temozolomide, 
and cisplatin. (1,45) (1,29,30,45).  Mitomycin C and cisplatin are considered as crosslink 
DNA that prevents DNA replication and transcription by the formation of DNA adducts 
within or between DNA strands (44). In contrast, temozolomide is used to treat brain tumor 
and considered as the methylating agent that generate damages which repaired via base 
excision repair (BER) (36,44). Besides, Mitomycin C and cisplatin are produced lesions 
that fixed by nucleotide excision repair (NER) and translation synthesis pathway (TLS) on 
quiescent cells in G0/G1 phase. Whereas in replicating cells in S phase are repaired by 
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Most alkylating agents which cause killing of tumors cells are bifunctional 
alkylating agents. These agents have two alkylating groups to form inter-stand cross links 
and intra-strand cross links, such as cisplatin (29,30) (table 3). Cisplatin has been shown 
inhibiting in replication S phase through breaking double stand break that repaired by non-
homologous end-joining (NHEJ) or homologous repair (HR) which are dependent on 
recruitment of specialized DNA polymerase pol eta to help to fill gaps and protect cells 
from the toxic effect of double strand break (52,54).  
However, cisplatin has shown inhibiting ATR kinase signaling through G1 phase 
on quiescent cells treated with ATR kinase inhibitors which are ongoing in clinical trials 
to promotes cell killing more than cisplatin alone and decreasing resistance of cisplatin 
(20,27-30). Suggesting that ATR kinase inhibitor and cisplatin have promising result to 
increase sensitivity of cisplatin to treat breast cancer patients. The possible repair 
mechanisms are nucleotide excision repair (NER) or translesian DNA synthesis on 
quiescent cells cisplatin with ATR inhibitors have been found that increase mutagenicity 
through increase induction of mono-ubiquitination PCNA that depend on translesian DNA 
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b. Topoisomerase inhibitors: 
Topoisomerase inhibitors are chemotherapies that inhibit topoisomerase enzymes 
that are responsible to regulate supercoiled DNA to relax lead to break in single strand 
DNA or double strand DNA break (1,29,30). They are classified as Topoisomerase I or II 
inhibitors. Camptothecin is topoisomerase I inhibitor which break single strand. Dr. 
Michael G Kemp had found that ATR inhibition partially protects quiescent cells from 
NAAF which is N-acetoxy-2-acetylaminoflurene (25,26). Camptothecin with ATR kinase 
inhibitor had been shown that inhibit replication in S and G2 phase in proliferating cells 
which is being tested in clinical trials (20,33). However, the second class is topoisomerase 
II inhibitor is Etoposide which is breaking double strand of DNA. Inhibit replication S and 
G2 phase on cell cycle on proliferating cells with ATR kinase inhibitors which is ongoing 
in clinical trials. (20,38,44). However, the process of transcription also generates 
transcriptional stress in DNA that must be relaxed by topoisomerases to allow for efficient 
transcription by RNA polymerases. Thus, topoisomerase inhibitors may also affect the 
function of non-replicating cells. 
 
c. Transcriptional stressors: 
 
Actinomycin D (ActD) and 5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside 
(DRB) inhibit RNA synthesis by impeding the movement of RNA polymerase II during 
transcription (25,26). Actinomycin D is transcription inhibitor that inhibits transcription 
and RNA polymerase through DNA intercalation, which binds to guanine and cytosine 
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base pairs (44).  DRB inhibits RNA polymerase transcription and messenger RNA 
transcription (44). Thus, ActD and DRB will all induce transcription stress by interfering 
with RNA polymerase movement (25,26). ActD and DRB have been shown that with ATR 
kinase inhibitors on quiescent cells inhibited ATR weakly compared to (NA-AAF) 
(25,26,34).  
d. Translational stressor: 
Translational inhibitor is Cycloheximide (CHX) which inhibits protein synthesis 
through elongation phase of protein synthesis in messenger RNA and translesion RNA in 
eukaryotic cells (44). CHX was used as a control for a general stress that is not known to 
generate genotoxic stress (25,26,53). In addition, CHX has been shown that the budding 
yeast homolog of ATR was essential in protein homeostasis. Thus, there may be other 
signals that can activate ATR besides canonical genotoxic stress (53). 
However, ATR kinase activation and function in genotoxin-treated quiescent cells 
or G1 stage on cell cycle are not accurately known. ATR inhibitors are being tested in 
clinical trials for human cancer patients (20). Thus, a few studies have indicated that ATR 
can be activated in non-replicating quiescent cells, which is important because only a 
minority of cells in the human body are undergoing replication at any given time. In 
contrast, most of the cells in the human body are in non-replicating quiescent or 
differentiated state. In addition, most tumor cells are in G1 phase in non-replicating state 
(25-28,33,34). A few previous studies have focused on agents that induce DNA lesions 
repaired by NER and have suggested a possible reliance on the TLS pathway that promote 
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mutagenesis in quiescent cells. Recently, Dr. Kemp’s lab had found that ATR inhibition 
with (NA-AAF) was partially protected cells from lethal effect when exposed on quiescent 
cells (25,26). However, more recent data from Dr. Kemp’s lab has been found that ATR 
inhibition UVB and cisplatin sensitize cells to apoptotic or cell death but increased in 
mutagenesis to examine long-term effect of ATR kinase inhibition on cell proliferative 
potential and mutagenesis in quiescent cells exposed to UVB and cisplatin (27,28).  
  Based on our previous data, we hypothesize ATR inhibition in quiescent cells have 
different functions when exposed to different type of genotoxins that generate variety of 
DNA lesions. This hypothesis will be tested by following three specific aims. The first aim 
is to determine how ATR kinase inhibition impacts acute cell survival following the 
treatment of quiescent cells with different genotoxic agents. The second aim is to 
characterize the effects of different genotoxic compounds on ATR kinase activation in non-
replicating cells. The last aim is to examine the long-term consequences of ATR kinase 
inhibition on cell proliferative potential and mutagenesis in quiescent cells exposed 
genotoxins. 
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MATERIALS AND METHODS 
1. Cell culture: 
The immortalized human HaCaT keratinocytes were cultured in DMEM/high 
glucose supplemented with 10% FBS clone III (Hyclone), 6 mM L-glutamine, 100 units/ml 
of penicillin, and 100 ug/ml of streptomycin at 37O C in a 5% CO2 humidified incubator. 
In proliferating HaCaT cells were subconfluent after it cultured with normal complete 
media 10% FBS while quiescent HaCaT cells were change the media to low serum 0.5% 
FBS clone III (Hyclone) DMEM/high glucose after it reach confluency two or three days. 
Next two days HaCaT cell were treated with DMSO or ATR inhibitor VE-821, VE-822, 
or AZD6738 (Selleckchem) for 30 min prior to use different DNA damaging agents. These 
are cisplatin (Sigma) was dissolved in PBS at a 3 mM stock concentration, camptothecin 
(Sigma) was diluted with DMSO at a 10 mM and a 1 mM stock concentration, actinomycin 
D (Sigma) was diluted from 1 mg/ml concentrated stock with DMSO to make 100ug/ml 
and 10 ug/ml stock concentration, etoposide (Sigma) was diluted with DMSO at a 50 uM 
stock concentration, cycloheximide (Sigma) was dissolved in sterile water to be 20 mg/ml 
stock concentration, mitomycin C (Sigma) of 2 mg was dissolved in 4 ml of sterile water 
to be 0.5 mg/ml  at a 1.5 mM stock concentration, 5,6-Dichlorobenzimidazole 1-beta-D-
ribofuranoside (DRB) (Sigma) was dissolved in 1.57 ml DMSO to be a 100 mM stock 
concentration, temozolomide (Sigma) was dissolved in 1.29 ml of DMSO at a 100 mM 
stock concentration. Quiescent HaCaT cells were exposed to DMSO as a (vehicle), 
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spironolactone (APExBio) was dissolved in DMSO at 10 uM stock concentration, and 
triptolide (Sigma) was dissolved in DMSO at 1 mM stock concentration.  Cells remained 
in the incubator for 4 hr or 24 hr to BrdU dot blot, MTT assay, immunoblotting/chromatin 
fractionation, and clonogenic survival assay. 
2. BrdU dot blot: 
Bromodeoxyuridine (BrdU) was added 10 ug/ml to a final concentration to 
proliferating HaCaT cells and quiescent HaCaT cells for 30 min prior harvesting the cells. 
The genomic DNA was purified by using the GenElute Mammalian Genomic DNA 
Miniprep kit (Sigma). Then, quantifying the genomic DNA with PicoGreen florescence 
(Invitrogen) on a Synergy H1 Hybrid Multi-Mode microplate reader (BioRad).  After that, 
DNA was immobilized on nitrocellulose, dried, and immunodot blotting with antibodies 
against BrdU (Sigma) or ssDNA (Millipore) at 1:5000 dilution in 10 ml TBST as previous 
described (25-28). 
3. MTT assay: 
Acute cell survival was determined by using (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, a tetrazole) staining which was performed using 96 well 
plates and survival determined after two days following treatment as mentioned before. 
Discard media from 96 well plates and add 1.25 ml of 5 mg/ml MTT solution to 23.75 
ml of low serum medium at a 0.25mg/ml MTT final concentration. Pour solution of 50 
ml tube to the boat and use multichannel pipettor of 100uL to each well. Incubate 96 well 
plate at 37oC CO2 incubator for 1 hr. Then, remove or aspirate MTT-reagent containing 
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medium and add 100 ul of DMSO to each well to solubilize the MTT dye, then put it on 
the shaker to ensure it solubilize completely. Measure at 570 nm absorbance from reader 
plate (Bio-Rad) and calculate relative survival and standard deviation by comparing 
treated samples with DNA damaging agents to the untreated DMSO control group and 
each of the ATR inhibitor-treated samples. 
4. Immunoblotting/chromatin fractionation: 
After quiescent HaCaT cells treated for 4 hr or 24 hr, cells were washed with cold 
PBS and scrape cells by cell scraper. Then, transfer cells to 1.5 ml microfuge tubes on 
the ice and centrifuge the samples for 4 hr at 4000 rpm. Aspirate the PBS without 
disturbing the cell pellet. Then, cells were lysed for 20 min on ice in 20 mM Tris-HCl 
(PH 7.4), 150 mM NaCl, 1mM EDTA, 1mM EGTA, and 1% Triton X-100. After that, 
cells were centrifuged in a cold centrifuge at maximum speed for 15 min at 4oC and 
soluble lysates were transferred to new tubes. While chromatin- associated proteins were 
obtained from cells by two times extractions with cytoskeletal buffer (10 mM Tris-HCL 
pH 7.4, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, 1 mM NaVO3, 10 
mM NaF,0.1 % Triton X-100). Then, sonicate them for 10 pulse per two times by 
sonicator. Soluble and chromatin lysates were separated by using SDS-PAGE in equal 
amounts. Then, transferred to nitrocellulose membrane, and stained with Ponceau S. 
After that, washed 2-3 times with TBST (Tris-buffered saline containing 0.1 %Tween-
20) and blocked in 5% milk in TBST. Probe them with primary antibodies with diluted 
with 1:2000 of Actin (BETHYL, A300-485A), phosphor-p53(Ser15) (Cell signaling 
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9284S), phosphor-ATR(Thr1989) (Gene Tex, GTX 128145), PCNA (Santa Cruz 
Biotechnology, sc-56), or Ubiquityl-PCNA (Lys146) (Cell signaling,13439S) in 
overnight with TBST. After washing five times for five min, secondary antibodies were 
probe them in 5% milk in 1xTBST in 1:2000 dilution. Secondary antibodies included 
horseradish peroxidase (HRP)-linked goat anti-Rabbit IgG (Invitrogen) and goat anti-
Mouse IgG (Invitrogen) for Ubiquity-PCNA. Then visualized by using clarity Western 
ECL substrate (Bio-Rad) or Supersignal West Femto substrate (Thermo Scientific) to 
detect chemilunescence signals by using a Molecular Imager Chemi-Doc XRS+ imaging 
system. Signals or bands were detected by using Image Lab (Bio-Rad) (25-28). 
5. Clonogenic Survival assay: 
Quiescent HaCaT cells were replaced drug-containing medium with fresh 
0.5% FBS low serum media, after it treated for two days in 6 well plates. Then, incubate 
cells for another three days and trypsinize cells for re-plating at 100 cells per 10 cm plate 
containing 10 ml of complete 10% FBS media. After that, incubate cells for two weeks 
and change the media with fresh complete 10% FBS media after one week. Finally, cells 
were stained with crystal violet after cells washed by PBS and fixed them by cold 
methanol for 20 min. After plate dried, cells were counted the number of colonies and 
determined the relative survival of the treatment plates and normalized with untreated 
control plates DMSO or ATR inhibitor (VE-821) (27,28). 
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RESULTS 
1. Validation of the non-replicating status of quiescent HaCaT keratinocytes by 
using BrdU labeling. 
To validate that our cell culture conditions can generate non-replicating 
quiescent HaCaT cells and proliferating HaCaT cells, BrdU labeling and 
quantification was carried out on the two populations of cells. Proliferating cells 
were grown to be sub-confluent about 50-60% confluency with 10% FBS serum 
media. In contrast, quiescent cells were grown to be confluent (about 95% 
confluency) then changed media with 0.5% FBS media (figure 8A). We confirmed 
the cellular proliferation to validate differences between quiescent cells and 
proliferating cells by adding 10 µg/ml of BrdU for 30 min. Then, the purification 
of the genomic DNA was quantified by PicoGreen kit and visualized by conducting 
immunoblotting BrdU-labeled genomic DNA with reprobing with anti ssDNA 
antibody as a control and anti-BrdU antibody. Relative DNA synthesis of 
proliferating HaCaT cells was higher than quiescent HaCaT cells. Thus, BrdU 
incorporated into proliferating HaCaT cell while in quiescent HaCaT cells have a 
few enough spaces to be incorporated less than in replicating cells (figure 8B). 






























Figure 8: Validation of the non-replicating status of quiescent HaCaT 
keratinocytes by using the BrdU labelling. (A) HaCaT cells in replication state 
with 10% FBS serum media while non- replication state it become confluent 
with 0.5% FBS media. (B) replication and non-replication cells were added 10 
µg/ml BrdU for 30 min to purify the genomic DNA, quantify genomic DNA 
with PicoGreen kit and immunodot blotting BrdU-labeled genomic DNA.  
Blots were re-probed with anti-ssDNA antibody as control or anti-BrdU 
antibody. Relative incorporation of BrdU from two separate experiments was 








2. Quiescent cells are less sensitive to the acute effects of genotoxic agents than 
proliferating cells. 
To determine how the different genotoxic agents impact acute cell survival, 
quiescent and replicating cells were treated with increasing concentrations of 
various genotoxic agents and then cell viability was measured. First, non-
replicating quiescent HaCaT cells or replicating HaCaT cells were grown to be 
confluent with low serum media or sub-confluent with high serum media, 
respectively, as (in figure 8A). 
After that, non-replicating quiescent HaCaT cells or replicating HaCaT cells 
were treated with increasing concentrations of different classes of genotoxic 
compounds. These are alkylating agent: mitomycin C (figure 9A), temozolomide 
(figure 9B), and cisplatin (figure 9C); topoisomerase inhibitors: camptothecin, 
which inhibit topoisomerase I (figure 9D), and etoposide, which inhibit 
topoisomerase II (figure 9E); transcriptional stressors: actinomycin D (figure 9F), 
and 5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside (DRB) (figure 9G), and 
the translational stressor: cycloheximide (figure 9H). Finally, after two days of 
treatment, non-replicating quiescent HaCaT cells or replicating HaCaT cells were 
stained by MTT. Relative survival and standard deviation were quantified and 
graphed. In general, most of the genotoxic compounds are significantly different 
between quiescent and proliferating HaCaT cells. Therefore, quiescent HaCaT cells 
are more resistant to be lethal than in replicating HaCaT cells, as shown in Dr. 
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Kemp’s articles, except temozolomide has no difference between quiescent or 














Figure 9: Comparison of cell survival in replicating and non-replicating HaCaT cells 
treated with different DNA damaging agents and genotoxic stressors. Proliferating 
(replicating) and quiescent (non-replicating) HaCaT cells were treated with the 
increasing concentrations of the indicated compounds. Then cell survival was 
assessed 2 days later by using an MTT assay. (A) Mitomycin C, (B) Temozolomide 
(TMZ), (C) Cisplatin, (D) Camptothecin, (E) Etoposide, (F) Actinomycin D, (G) 5,6-
Dichlorobenzimidazole 1-beta-D-ribofuranoside (DRB), and (H)Cycloheximide. 
Relative survival was performed 2 times in replicating HaCaT cells and 4 times in 














3. ATR kinase inhibition in genotoxin-treated quiescent cells does not impact 
acute survival. 
To determine how ATR kinase inhibition impacts acute cell survival following the 
treatment of quiescent cells with different genotoxic agents. As in figure 9, quiescent 
HaCaT cells and proliferating HaCaT cells were treated with vehicle (DMSO) or different 
ATR kinase inhibitors (VE-821, VE-822, and AZD6738) for 30 min followed by the 
different genotoxic agent in a dose-dependent manner. Quiescent cells were then treated 
with the various genotoxic compounds as described above and analyzed by MTT assay. 
  ATR kinase inhibition has varying effects on acute survival in replication cells 
treated with different genotoxins, as shown on the right side (figure 10). However, ATR 
kinase inhibition generally has no significant effect on acute survival in quiescent cells, as 
shown on the left side (figure 10). The rationale for measuring the survival is to test the 
response to DNA damage and genotoxic stress with ATR kinase inhibitors. Thus, 
proliferating HaCaT cells are more sensitive to lethal effect than quiescent HaCaT cells, 
which treated with ATR inhibitors and exposed to a different type of genotoxins, except 
DRB is having the opposite impact than others genotoxins because it may not inhibit 



















































           Figure 10: ATR kinase inhibition has differing effects on acute cell survival 
following treatment of quiescent and proliferating cells with different genotoxic 
compounds. Proliferating and quiescent HaCaT cells were pre-treated with vehicle 
(DMSO) or the ATR inhibitor (ATRi) VE-821, VE-822 or AZD6738 for 30 min 
before treatment with the indicated concentrations of genotoxic compounds. MTT 
assays were used to measure cell survival 2 days later.  (A) Mitomycin C, (B) 
Temozolomide (TMZ), (C) Cisplatin, (D) Camptothecin, (E) Etoposide, (F) 
Actinomycin D, (G) 5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside (DRB), 
and (H)Cycloheximide. Relative survival was performed 2 times in replicating 
HaCaT cells and 4 times in quiescent HaCaT cells with the average and standard 










4. Many genotoxins induce ATR kinase activation in quiescent cells. 
 The data presented in Figure 10 indicated that ATR kinase inhibition did not 
affect acute cell survival in the quiescent cells. To determine if ATR was activated in 
these cells, we next carried out experiments in which we treated quiescent HaCaT 
cells with the genotoxin at concentrations that were shown to inhibit survival in the 
proliferating state. Quiescent cells were treated with DMSO or ATR kinase inhibitor 
(VE-821) for 30 min. They were then exposed to different genotoxins in 
concentrations for 24 hr that show effect in quiescent HaCaT cells in acute survival 
as in (figure11). These are A) Mitomycin C (20 µM), (B) Temozolomide (TMZ) in 
(500 µM), (C) Cisplatin (40 µM), (D) Camptothecin (20 µM), (E) Etoposide (250 
µM), (F) Actinomycin D (100 ng/ml), (G) 5,6-Dichlorobenzimidazole 1-beta-D-
ribofuranoside (DRB) (100 µM), and (H) cycloheximide (50 µg/ml). 
After that, cells were harvested, and lysates were probed for p53 and/or ATR 
phosphorylation by immunoblotting. Because p53 gave the strongest and most 
consistent results among the different genotoxins, we focused our analyses on p53 
phosphorylation. In quiescent HaCaT cells, p53 phosphorylation was increased in 
response to all of the different genotoxic compounds except DRB. Moreover, 
treatment with the ATR inhibitor VE-821 significantly blocked ATR and/or p53 
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phosphorylation in response to most of the genotoxins. Residual p53 phosphorylation 
in the presence of the ATR inhibitor is likely due to the action of the related kinase 
ATM, which is known to be activated in response to DNA double-strand breaks 
(25,26,33,34). Nonetheless, these results demonstrate that ATR kinase signaling is 
activated in quiescent HaCaT cells in response to a variety of different types of 
genotoxic compounds. Thus, replication stress during S phase is not the only signal 














Figure 11. ATR kinase signaling is activated in quiescent cells in response to a 
variety of different genotoxic compounds. Quiescent HaCaT cells were treated with 
vehicle (DMSO) or the ATR kinase inhibitor (VE-821; 10 µM) for 30 min before 
exposure to the indicated genotoxins. Cell lysates were prepared 24 hr later and were 
analyzed by western blotting with antibodies against phosphorylated ATR 
(Thr1989), phosphorylated p53 (Ser15) and Actin. The following concentrations of 
genotoxins were used(A) Mitomycin C (20 µM), (B) Temozolomide (TMZ) in (500 
µM), (C) Cisplatin (40 µM), (D) Camptothecin (20 µM), (E) Etoposide (250 µM), 
(F) Actinomycin D (100 ng/ml), (G) 5,6-Dichlorobenzimidazole 1-beta-D-




5. Effects of ATR kinase inhibition on TLS pathway activation in genotoxin-
treated quiescent cells. 
To examine possible functions for ATR kinase signaling in quiescent cells 
unrelated to acute viability, we next examined a potential role in mutagenesis by 
monitoring activation of the translesion synthesis (TLS) pathway. The TLS 
pathway is potentially error-prone and may increase the risk of mutation and cell 
death (27,28,41-43,48). Quiescent HaCaT cells were treated with DMSO or ATR 
kinase inhibitor (VE-821) for 30 min and then were exposed to different genotoxins 
for 4 hr (figure 12), 24 hr (figure 13). After two days, quiescent HaCaT cells were 
harvested and extracted to enrich for chromatin-associated proteins. PCNA 
becomes loaded onto DNA during DNA repair synthesis and becomes mono-
ubiquitinated on Lys164 upon activation of the TLS pathway. 
As shown in figure 12, there is an induction of PCNA mono-ubiquitination 
at lysine 164 after 4 hr of treatment with mitomycin C (figure 12 A), temozolomide 
(figure 12 B), and cisplatin (figure 12 C). All three of these compounds induce the 
formation of adducts on DNA that are repaired by either NER or BER and thus 
require PCNA to complete DNA repair synthesis. Though some of the agents 
induced an increase in chromatin-associated PCNA, they did not stimulate 
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significant PCNA mono-ubiquitination and thus do not seem to induce the TLS 
pathway. However, ATR kinase inhibition did not cause any difference in PCNA 
mono-ub after treated with these drugs. We then repeated the experiments but 
treated for a longer period of time (24 hr.). As previously reported (27), ATR kinase 
inhibition stimulated PCNA mono-ubiquitination after cisplatin treatment (figure 
13 C). Similarly, we observed that treatment mitomycin C resulted in PCNA mono-
ubiquitination that was stimulated by ATR kinase inhibition (figure 13 A). In 
contrast, after 24 hr treatment of temozolomide (figure 13 B) with ATR kinase 
inhibition did not cause any increase in PCNA mono-ub. 
  Then, dose response of mitomycin C and temozolomide were performed 
(figure 14) because mitomycin C and temozolomide treatment resulted in the most 
robust activation of the TLS pathway, we performed dose response experiments 
monitoring PCNA mono-ubiquitination after 4 hr and 24 in the presence and 
absence of the ATR inhibitor. As shown in figure 14, we observed that that ATR 
kinase inhibition caused an increase in PCNA mono-ub after treated for 24 hr with 
different doses of mitomycin C but not with temozolomide. 
In conclusion, ATR kinase inhibition caused an increase in PCNA mono-
ub after treatment with mitomycin C and cisplatin in quiescent cells. Both of these 
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agents are bifunctional alkylating agent that induce DNA lesions that are repaired 
by NER (1,29,30,35) and thus ATR may function in this process to limit the 
dependence on TLS polymerases. In contrast, ATR kinase signaling does not 
appear to be involved in the DNA repair synthesis that takes place in response to 
the monofunctional methylation agent temozolomide, which induces methyl 
adducts repaired by BER. Thus, ATR kinase inhibitors with some chemotherapies 
as cisplatin and mitomycin C may increase the risk of mutation and secondary 
cancer to the non-replicating cells of the human’s cells (27,35). ATR kinase 
inhibition had been studied in replicating cells with anticancer drugs that decreased 





Figure 12: Examination of the effects of ATR kinase inhibition on TLS pathway 
activation in genotoxin-treated quiescent cells in shorter time. Quiescent HaCaT cells 
were treated with vehicle (DMSO) or the ATR kinase inhibitor (VE-821; 10 µM) for 
30 min before exposure to the indicated genotoxins. Cell lysates were prepared 4 hr 
later and were analyzed by western blotting with antibodies against PCNA mono-ub, 
total PCNA and Ponceau staining as a control. The following concentrations of 
genotoxins were used: (A) Mitomycin C (20 µM), (B) Temozolomide (TMZ) in (500 
µM), (C) Cisplatin (40 µM), (D) Camptothecin (20 µM), (E) Etoposide (250 µM), (F) 
Actinomycin D (100 ng/ml), (G) 5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside 




Figure 13: The effect of ATR inhibition in elevation in PCNA mono-ubiquitination 
in genotoxin-treated in quiescent cells in longer time treatment. Quiescent HaCaT 
cells were treated with vehicle (DMSO) or the ATR kinase inhibitor (VE-821; 10 
µM) for 30 min before exposure to the indicated genotoxins. Cell lysates were 
prepared 24 hr later and were analyzed by western blotting with antibodies against 
PCNA mono-ub, total PCNA and Ponceau staining as a control. The following 
concentrations of genotoxins were used: (A) Mitomycin C (2.5 µM), (B) 
Temozolomide (TMZ) in (500 µM), (C) Cisplatin (40 µM), (D) Camptothecin (20 
µM), (E) Etoposide (250 µM), (F) Actinomycin D (100 ng/ml), (G) 5,6-





             Figure 14: Mitomycin C and temozolomide dose response in different two times 
points. Quiescent HaCaT cells were treated with vehicle (DMSO) or the ATR kinase 
inhibitor (VE-821; 10 µM) for 30 min before exposure to the indicated genotoxins. 
Cell lysates were prepared 4 hr., 24hr later and were analyzed by western blotting with 
antibodies against PCNA mono-ub, total PCNA and Ponceau staining as a control. 
The following concentrations of genotoxins were used: (A) Mitomycin C dose 
response (2.5 uM, 2uM,10 uM, 20uM, and 30 uM), (B) Temozolomide (TMZ) dose 






6.  The effect of NER inhibitors on TLS pathway activation and ATR kinase 
signaling in genotoxin-treated quiescent cells. 
            To see the effect of PCNA mono-ubiquitination and ATR kinase signaling with 
using NER inhibitors. After 2 days of quiescent HaCaT cells were confluent with low 
serum media to be confluent from proliferating in S phase to non-replication in 
G0/G1stage. Then after 2 days, cells were pre-treated 2 hr or 30 min with spironolactone, 
triptolide, or DMSO, respectively. Cells were followed with mitomycin C (20 uM) or 
temozolomide (500 uM) for 4 hr or 24 hr treatment. After that, cells were harvested and 
cell lysates either by fractionation buffer to extract chromatin-fractionation three times 
to see the effect of PCNA mono-ubiquitination or by lysate buffer in soluble lysate to see 
the effect of ATR signaling pathway activation after 4hr or 24hr, respectively. Finally, 
western blot assays were performed (figure 15). 
        The effect of PCNA mono-ubiquitination by using NER inhibitors (spironolactone 
and triptolide) followed with mitomycin C or temozolomide for 4 hr or 24 hr treatment 
(figure 16). We can see from figure 16, when quiescent HaCaT cells treated with 
mitomycin C in the top left side the treatment decreased the induction of PCNA mono-ub 
with spironolactone or triptolide for 4 hr treatment. Therefore, the use of NER inhibitors 
(spironolactone and triptolide) inhibits the induction of PCNA mono-ub. Similarly, Dr. 
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Kemp’s lab previously has been shown that inhibiting NER by (spironolactone or 
triptolide) blocked PCNA mono-ub with cisplatin and UVB, which TLS pathway may be 
required to fill in NER gaps (27,28). This suggests that the TLS pathway may be needed 
to fill gaps in NER during quiescent cells to inhibit the single-strand DNA break from 
converting to double-strand DNA break, which is the one of the most dangerous and toxic 
DNA lesions (51,52,54).  However, mitomycin C with NER inhibitors showed toxicity to 
the quiescent cells, especially when cells were treated with triptolide for 24 hr.  Thus, we 
cannot see the effect of NER inhibitors with PCNA mono-Ub because of the toxicity of 
these drugs on cells treated with either mitomycin C or temozolomide for 24 hr. 
Temozolomide induces BER that has been considered as not toxic as mitomycin C which 
likely to generate of sufficient single strand to activate TLS pathway. Also, the 
temozolomide result is suggesting that DNA polymerase on the BER pathway prevented 
RPA and PCNA on single-strand intermediates on quiescent cells to be error-prone TLS, 
which is the opposite of lesions (52,54). 
The effect of ATR kinase signaling pathway and using NER inhibitors 
(spironolactone and triptolide) followed by treatment with mitomycin C or temozolomide 
was examined at 4 hr or 24 hr time points (figure 17). We can see with mitomycin C 
treatment for 24 hr is more dependent on ATR signaling pathway because there is 
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increasing phosphorylation of p-53(Ser15) and ATR (Thr1989) when exposed to NER 
inhibitors or alone. Similarly, previous studies have shown that pre-treatment with NER 
inhibitors blocked cisplatin and UVB  dependent  ATR kinase signaling through 
phosphorylation of ATR and p53. Thus, they conclude that ATR kinase signaling on 
quiescent cells are dependent on NER pathway when  exposed to UVB or cisplatin 











Figure 15: Diagram of the effect of PCNA mono-ubiquitination and 
ATR kinase signaling with NER inhibitors. HaCaT quiescent cells were 
confluent and changed media to low serum 0.5% serum after 2 days from 
S phase in proliferating cells to be confluence in G0/G1 phase in 
quiescent cells. Then, after 2 days, cells were treated with spironolactone, 
triptolide, or DMSO before treated with mitomycin C (20 uM) or 
temozolomide (500 uM) by 2 hr or 30 min, respectively.  After that, cells 
were harvested and cell lysates either by fractionation buffer to extract 
chromatin-fractionation three times or by lysate buffer in soluble lysate 






Figure 16: The effect of PCNA mono-ubiquitination by using NER inhibitors 
(spironolactone and triptolide) followed with mitomycin C or temozolomide for 4 
hr or 24 hr treatment. Quiescent HaCaT cells were pre-treated with spironolactone, 
triptolide, or DMSO as vehicle for 2hr or 30 min, respectively. Then, cells were 
followed with mitomycin C (20 uM) or temozolomide (500 uM). Finally, cells were 
harvested and lysated with fractionation buffer for three times and cells were 












Figure 17: The effect of ATR kinase signaling and NER inhibitors exposed to 
mitomycin C or temozolomide in different times points. Quiescent HaCaT were 
treated with spironolactone, triptolide, or DMSO as a vehicle for 2 hr or 30 min, 
respectively. Then, cells were followed with mitomycin C or Temozolomide for 
4hr or 24 hr treatment. Finally, cells were harvested and cell lysates with lysate 









7. Effect of ATR kinase inhibition on the clonogenic survival of quiescent cells 
following their induction of the proliferative state. 
   Because the different genotoxins induced ATR kinase signalling in the 
quiescent cells (figure 11) but ATR kinase inhibition had little effect on acute 
viability in quiescent cells (figure 10), we next wanted to determine whether ATR 
kinase inhibition impacts the ability of quiescent cells to proliferate and form colonies 
upon withdrawal of the different genotoxins. We therefore carried out clonogenic 
survival assays with after exposure of quiescent cells to the different genotoxic 
agents. Quiescent HaCaT cells were treated with DMSO or ATR inhibitor (VE-821) 
for 30 min followed by genotoxic compound treatment for two days. After two days, 
the culture medium was changed media to low serum media and the cells were 
cultured for an additional 3 days. The cells were then trypsizined and re-plateed at 
low density to monitor colony formation.  Cells were incubated for two weeks and 
were then stained with crystal violet to visualize and count the colonies (27,28). A 
schematic of this experimental methodology is shown in figure 18. 
        From figure 19, ATR kinase inhibition with different genotoxic compounds 
have not consistent results, but may be decreased clonogenic generally. Dr. Kemp’s 
lab previously showed that ATR kinase inhibition with UVB radiation have 
significantly decreased clonogenic survival but not with cisplatin which have not 




Figure 18: Clonogenic survival assay diagram. After two days of quiescent HaCaT 
cells were confluent with low serum media and then treated with DMSO or ATR 
inhibitors (VE-821) for 30 min followed by using genotoxic agents. It changed 
media with 0.5% FBS serum media for three days and then re-plate cells and 
trypsinize it with two weeks incubated. It changed media with 10% FBS serum after 

















Figure 19: Effect of ATR kinase inhibition on the clonogenic survival assay of 
quiescent HaCaT cells exposed to different genotoxic agents. Quiescent HaCaT cells 
were treated with DMSO or ATR inhibitor (VE-821) for 30 min followed with 
different genotoxic compounds in concentration were used: (A) Mitomycin C (20 
µM), (B) Temozolomide (TMZ) in (500 µM), (C) Cisplatin (40 µM), (D) 
Camptothecin (20 µM), (E) Etoposide (250 µM), (F) Actinomycin D (100 ng/ml), 
(G) 5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside (DRB) (100 µM), and (H) 
Cycloheximide (50 µg/ml). Relative survival cells were quantified (Mean +/- SE of 











There are different types of DNA damaging agents that cause a variety of DNA 
lesions which employ specific types of DNA repair mechanisms. Hence, many of these 
defects in DNA repair mechanisms have been linked to human disease and increase the 
risk of cancers and mutations. Many DNA damaging agents also induce the activation of 
ATR kinase signaling. However, most of our knowledge on ATR kinase activation and 
function is limited to replicating cells, where ATR regulates replication origin firing, 
replication fork stabilization, and cell cycle progression. Because most cells in the body 
are in a non-replicating quiescent or differentiated state, it is important to understand how 
DNA damaging agents impact non-replicating cell function and how ATR modulates these 
effects. As shown in figure 11, ATR kinase is activated under normal conditions after 
quiescent cells are exposed to different types of genotoxins. The mechanisms by which 
each genotoxin activates ATR signaling remain to be determined. However, as both DNA 
repair intermediates and RNA polymerase stalling potentially involve the generation of 
long stretches of single-stranded DNA, ATR activation in quiescent cells may exhibit 
similarities to canonical activation by replication fork stalling. The functions of ATR in 
non-replicating cells is also important to determine. ATR kinase inhibition in proliferating 
cells generally sensitizes the cells to undergo cell death in response to treatment with 
different genotoxins. In contrast, as shown in figure 10, ATR kinase inhibition generally 
has no significant impact on acute survival in quiescent cells. However, the observation 
that ATR kinase signaling is activated in quiescent cells treated with a variety of different 
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genotoxins (figure 11) implies that ATR kinase may have other functions in quiescent cells 
that do not directly impact acute survival. These functions may include the regulation of 
RNA splicing (59) or translesion DNA synthesis (TLS) (25-28,37).  
Most DNA repair mechanisms involve some level of DNA synthesis to replace 
damaged nucleotides removed during the repair process. For example, in cells exposed to 
UV radiation or cisplatin, the nucleotide excision repair system removes the damaged 
nucleotides in the form of 30-nt-long DNA oligonucleotide. This process leaves a 30-nt 
single-stranded DNA gap in the DNA that must be filled by DNA synthesis to restore the 
duplex to its native double-stranded state. Though the replicative polymerases pol delta 
and epsilon have long been assumed to be involved in this gap filling synthesis, more recent 
data show that TLS polymerases may be required for this process (51, 60, 61). The 
recruitment of TLS polymerases to sites of DNA damage and repair requires the mono-
ubiquitination of the polymerase clamp protein PCNA. In the case of UVB radiation and 
cisplatin, which induce lesions removed by nucleotide excision repair, ATR kinase 
inhibition results in an increased level of PCNA mono-ubiquitination (27, 28). These 
results indicate that DNA repair synthesis is more reliant on TLS polymerases when ATR 
is inactive in quiescent cells.  The alkylating agent mitomycin C (MMC) is similar to 
cisplatin in that it induces monoadduct and inter-strand crosslinks that require the 
nucleotide excision repair machinery for damage removal. As shown in figure 13 and 14, 
ATR kinase inhibition in MMC-treated quiescent cells results in a higher level of PCNA 
mono-ubiquitination. Moreover, treatment with the nucleotide excision repair inhibitor 
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spironolactone partially abrogates both MMC-induced ATR signaling (figure 17) and 
PCNA mono-ubiquitination (figure 16), which indicates that both DNA damage response 
processes are dependent on nucleotide excision repair in quiescent cells.  Thus, ATR kinase 
inhibitors may induce mutagenesis and elevate the risk of carcinogenesis in humans 
undergoing chemotherapies regimens that involve both ATR kinase inhibitors and a DNA 
damaging chemotherapy drug. 
In contrast, temozolomide (TMZ) treatment generates smaller methylated purine 
lesions that can be removed from DNA by the base excision repair system. During BER, 
PCNA becomes loaded onto DNA to allow DNA polymerase delta or epsilon to carry out 
DNA repair synthesis, in a manner similar to nucleotide excision repair. Moreover, the data 
in figure 13 demonstrate that PCNA becomes mono-ubiquitinated after TMZ treatment in 
quiescent cells, which suggests that some BER DNA synthesis involves TLS polymerases. 
However, the observation that ATR inhibition does not further exacerbate this PCNA 
mono-ubiquitination (figure 13, 14) indicates that ATR does not affect repair synthesis 
during long-patch BER, unlike the situation with UVB, cisplatin, and MMC (figure 20). A 
possibly explanation for this difference is the extent of single-stranded DNA generation 
during NER and BER. NER gaps are much larger than BER gaps, and thus only NER gaps 
may provide sufficient amounts of single-stranded DNA for RPA binding and subsequent 
ATR recruitment to the repair gap to regulate gap filling synthesis. However, future studies 
will be necessary to test this hypothesis. 
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Figure 20: Schematic summarizing the effect of the effect of ATR kinase inhibition 
in temozolomide, mitomycin C, cisplatin, and UVB treated quiescent cells. Most 
genotoxins under normal conditions are repaired by different DNA repair 
mechanisms to fill gaps by DNA synthesis after ATR becomes activated. However, 
when ATR inhibited, the gap filling process depend on the translesien synthesis TLS 
pathway because it is increased in PCNA monoubiquitination mitomycin C, 
cisplatin, or UVB-treated quiescent cells. These leads to DNA adducts to be repaired 
by the NER. These genotoxins can result in increasing mutagenesis or cell death. In 
contrast, temozolomide is generated single methyl group on guanine which it is 
repaired by BER machinery. Thus, after ATR inhibited, the gap filling process 
becomes more dependent on PCNA polyubiquitination to fill gaps without PCNA 
and RPA, which can result in increasing cell survival because it is error-prone lesion 




To summarize the results in three points: 1) Most of the genotoxins lead to the 
activation of ATR kinase signaling in quiescent cells. 2) Acute cell viability for genotoxins 
were not significantly affected by ATR kinase inhibition, except for cisplatin and modestly 
for MMC. 3) None of these genotoxic compounds induced much PCNA mono-
ubiquitination except MMC and TMZ. These findings provide the potential to understand 
the role of the ATR kinase for the treatment and prevention of human cancers. These 
provide new insight on how modulation of ATR dependent on DNA damage signaling, 
which has therapeutic effects of mitigating or limiting the toxicity of certain genotoxic 
compounds. Hence, as we know that ATR inhibitors are currently in clinical afflictions as 
anti-cancer treatment with or without chemotherapies or radiotherapies, thus, it is essential 
to mitigate or limit the toxicity or adverse effects of DNA damaging anti-cancer agents. 
ATR kinase inhibition may have positive or negative results with different types of 
genotoxins. Thus, mitomycin C, cisplatin, UVB with ATR inhibitors should be monitored 
because it increases TLS, which leads to increase mutation and secondary cancers. 
 For future studies, we need determine how ATR impacts TLS activation 
(mechanism) and whether ATR affects recruitment of specific TLS polymerase to damaged 
DNA.  In addition, we need to identify relevant substrates for ATR in genotoxin-treated 
quiescent cells. Moreover, are these effects seen in other non-replicating cell types 
including differentiated cells and senescent cells that compose most tissues in vivo. Finally, 
we need to confirm these results on three dimensional cultured microenvironments, which 
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mimic the  in vivo experiments as in human’s bodies because 3D cultured cells have 
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